Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on milademetan PK
NCT03647202Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milademetan in acute myeloid leukemia (AML), Liposarcoma and solid tumor (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum plasma concentration at 120 hours and Area under the plasma concentration-time curve extrapolated to infinity. Started Aug 2018; status: completed.
02
Drugs
milademetan
03
Conditions
acute myeloid leukemia (AML)Liposarcomasolid tumor
Beyond the preview
Go deeper on NCT03647202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647202.